Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 February 2020 | Story Cobus van Jaarsveld | Photo Charl Devenish
Traffic Circle on the UFS Bloemfontein Campus
The Department of Protection Services shares how to #BSafe at traffic circles.

For the majority of drivers, one of the most confusing driving laws is the correct use of a traffic circle, especially in Bloemfontein with the large number of smaller traffic circles constructed over the past few years; also across the University of the Free State (UFS) Bloemfontein Campus.

“In fact, many motorists do not know that there is a difference between a larger traffic circle and a mini traffic circle, other than their size. Can you really be frustrated if someone cuts you off at a traffic circle if you don't know the rules? Arrive Alive has shed some light on the issue,” said Cobus van Jaarsveld, Assistant Director: Threat Detection, Investigations and Liaison in the UFS Department of Protection Services.

What is the difference between the two circles?

A traffic circle is classified as large when it has a minimum diameter of about 16 metres and a 1,5 to 2 metre flattened kerb, which allows heavy vehicles to drive onto a small section of the circle. A mini traffic circle is normally not more than seven to ten metres in diameter and the entire circle is mountable for heavy vehicles.

Are there different rules for each?

Yes – the rule of thumb is that mini traffic circles, which are usually found in residential areas, have the same rules as a four-way stop – first come first served. For larger traffic circles, which are usually found at busy crossings to assist with the traffic flow, you must give way to the right.

Rules to remember at a large traffic circle

As you arrive at a large traffic circle, traffic coming from your right has right of way, regardless of how many cars there are. Wait until there is a gap in the traffic and then ease slowly into the circle. Watch out for other traffic in the circle and be aware that they may not be using their indicators.

Use your indicators

Signal when you are going to turn – switch your indicator on immediately after passing the exit prior to the one you intend taking. If you are taking the first exit, i.e. you're turning left, then flick on your left indicator and keep in the outside/left-hand lane. Keeping in the outside/left-hand lane also works well if you're continuing straight ahead, as your exit is very close. After you've passed the left-turn exit and yours is next, signal left and you're free. If you're turning right or performing a U-turn, keep in the inside/right-hand lane. Only signal left and change into the left-hand lane once you've passed the other exits and only yours is ahead.

Rules to remember at a mini traffic circle

The first vehicle to cross the line has the right of way, so it really works on the same principle as a four-way stop or yield sign. Proceed in a clockwise direction around the circle, without driving on it.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept